

STEM CELL THERAPY FEATURED IN THE ROSE SHEET

-Company Continues to Pursue Distribution Partners-

December 15, 2009 - Stem Cell Therapy International Inc. (OTCBB: SCII) announced that it has been featured in the December 14 issue of The Rose Sheet, a weekly publication focused on the toiletries, fragrance and skin care industries. The article details the Company's agreement with Histostem Ltd. of South Korea ("Histostem") for the exclusive worldwide distribution rights to SteMixx, a stem cell based facial cream and may be accessed by visiting the investor page of Stem Cell Therapy's website at: <http://www.amsteminc.com>.

SCII will begin marketing SteMixx internationally beginning in the first quarter of 2010. As part of the product rollout the Company is exploring partnership opportunities that will enable it to create an optimal international distribution network.

Earlier this month SCII announced the terms of its agreement with Histostem Ltd. for the exclusive distribution rights to the Company's existing SteMixx line of stem cell based cosmetic products, as well as future products under development. Previously available for purchase only in Korea, SteMixx received approval last month from the Korean FDA as an effective cosmetic for the treatment of aging skin. SCII will seek similar product validations from regulatory agencies in the United States and Europe.

"SteMixx is a unique facial skin care product that combines the regenerative qualities of important proteins derived from umbilical cord stem cells with a naturally-occurring nucleoside that has been shown to have anti-inflammatory and tissue repair properties. In short, the proteins within SteMixx work with an individual's stem cells to revitalize the skin. These attributes, combined with our scientific formulations of natural plant extracts, make SteMixx a very powerful agent in the fight against the effects of aging on the skin," explains Dr. Hoon Han, President of Histostem and the inventor of SteMixx.

He added, "The source of the stem cells used to create SteMixx is non-controversial umbilical cord blood from documented, consenting donors under the highest degree of medical care and scientific processing."

David Stark, President of SCII commented, "We are seeking appropriate distribution partners for the worldwide launch of SteMixx, which is currently being produced at Histostem's manufacturing facility in South Korea. SteMixx may be marketed as a branded luxury cosmetic product or as a repackaged private label product depending on the needs of our distribution partners."

He added, "The Korean FDA approval has validated this product in the Korean market as a 'functional cosmetic' for the treatment of wrinkles and the effects of aging on the skin. We expect that this approval, combined with our Company's proven experience in the science and technology of stem cells, and the establishment of an efficient distribution network, will provide excitement to the launch and sustained momentum for the popularity of this product."

About Stem Cell Therapy International, Inc.

Stem Cell Therapy International, Inc. (OTC; SCII) is in the field of regenerative medicine. SCII (soon to have its name changed to AmStem Corporation) is a company devoted to the treatment of patients with stem cell transplantation therapy as well as providing the supplies of biological solutions containing new lines of stem cell products.

About AmStem International Corporation

AmStem is a new biotechnology company based in Northern California, in the watershed of stem cell innovation fueled by President Obama's recent announcement to lift Federal funding limitations for stem cell research. AmStem provides biotherapeutic and cosmetic stem cell products, stem cell collection and storage know-how, and access to nanotechnology vital to cutting edge stem cell research. Its web site is under construction at www.amsteminc.com.

About Histostem Co. Ltd.

Histostem was founded in Seoul, Korea in 2000, to date it has treated more than 500 patients with stem cells and currently has approximately 50 full-time employees and several part-time employees. Histostem's intellectual property portfolio consists of 6 patents that have been granted and 5 patents pending. To its knowledge Histostem is one of the very few stem cell companies in the world currently earning several million dollars in income from its products and technology. A comprehensive list of Histostem's achievements can be found at the company's website <http://www.histostem.co.kr> (click on English version when entering the site).

About the Pending Stock Purchase and Reorganization

Management is in the process of issuing the necessary shares and preparing the documents to complete all pre-closing requirements of the Stock Purchase and Reorganization agreement. Management expects that all of the pre-closing requirements will be completed shortly and the close of the stock purchase and reorganization agreement will occur prior to the end of the year.

Forward-Looking Statements

Some of the statements included in this press release, particularly those anticipating future clinical and business prospects for Stem Cell Therapy International, Inc., may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to obtain necessary capital, our ability to successfully complete the merger, successfully complete clinical trials; our ability to meet anticipated development timelines, our ability to establish global market for the cord blood cells, clinical trial results, successfully consummate future acquisitions, manufacturing capabilities or other factors; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release

speaking only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

CONTACTS:

Stem Cell Therapy International, Inc.
(813) 283-2556

Investor relations:

Jennifer Belodeau/John Nesbett
Institutional Marketing Services (IMS)
203.972.9200
IR@amsteminc.com

David Stark, CEO
DStark@amsteminc.com

Andrew Norstrud, CFO
Anorstrud@amsteminc.com